JEDDAH: A Saudi study has documented the safety of the AstraZeneca vaccine used to protect people against the coronavirus.
The results of the study, titled the “Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia,” were shared on Friday by the deputy minister of preventive health, Abdullah Assiri.
The cross-sectional study, conducted on 1,592 randomly selected vaccinees, measured the “estimated the safety and reactogenicity of the ChAdOx1-S vaccine as administered to adults after the first dose.”
No major side effects were observed and no breakthrough infection was reported during the observation period.
The results showed that 34.7 percent of the studied group reported a reaction after the first dose while none of the group had any reaction after the second.
Some of the side effects reported among the group were injection site pain in 30.5 percent, musculoskeletal symptoms in 27.5 percent, while 62.4 percent of males experienced more fever than females (37.6 percent).
The study also concluded that the rate of post-vaccine COVID-19 infection was 0.5 percent with zero hospitalization.